Ocular Hypertension (OHT)
12
2
2
7
Key Insights
Highlights
Success Rate
78% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
16.7%
2 terminated out of 12 trials
77.8%
-8.8% vs benchmark
17%
2 trials in Phase 3/4
14%
1 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 7 completed trials
Clinical Trials (12)
REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension
Direct vs Standard SLT for Glaucoma: A Noninferiority Trial
Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone
Qlaris Phase 2 Study of QLS-111 in POAG And/or OHT Patients
Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients
Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG
A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
Safety and Efficacy of Deep Wave Trabeculoplasty (DWT) in Primary Open Angle Glaucoma and Ocular Hypertension
Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma
Safety Study of Latanoprost Slow Release Insert
AL-54478 Proof of Concept Study
Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle Glaucoma